• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug & Device Pipeline News

Drug & Device Pipeline News

October 31, 2022
Company Drug/Device Medical Condition Status
Trials Authorized
Cellevolve CE-VST01-JC Progressive multifocal leukoencephalopathy IND approved by the FDA
Cour Pharmaceuticals CNP-106 Myasthenia gravis IND approved by the FDA
Nihon Medi-Physics NMK89 Cancer diagnostic IND approved by the FDA
Trials Initiated
Anixa Biosciences Breast cancer vaccine Breast cancer Initiation of phase 1b trial
Bio-Path Holdings BP1002 Refractory/relapsed acute myeloid leukemia Initiation of phase 1/1b trial
Corvus Pharmaceuticals Ciforadenant plus ipilimumab and nivolumab Metastatic renal cell cancer Initiation of phase 1b/2 trial
Sensorion SENS-401 (arazasetron) Cisplatin-induced ototoxicity Initiation of a phase 2a trial in France
Aphaia Pharma APH-012 Chronic weight management in people with obesity Initiation of phase 2 trial
Neurocrine Biosciences NBI-1117568 Schizophrenia in adults Initiation of phase 2 trial
Seelos Therapeutics SLS-005 (trehalose injection) Spinocerebellar ataxia type 3 Initiation of phase 2/3 trial
HUTCHMED Fruquintinib plus sintilimab Second-line treatment for locally advanced or metastatic renal cell carcinoma Initiation of phase 2/3 trial in China
Boehringer Ingelheim BI 1015550 Idiopathic pulmonary fibrosis Initiation of phase 3 trial
Codagenix CoviLiv COVID-19 vaccine COVID-19 Initiation of phase 3 trial
Finch Therapeutics CP101 Recurrent C. difficile infection Initiation of phase 3 trial
Approvals
AbbVie Rinvoq (upadacitinib) Nonradiographic axial spondyloarthritis in adults Approved by the FDA for new indication
AstraZeneca Imjudo (tremelimumab) plus Imfinzi (durvalumab) Unresectable hepatocellular carcinoma in adults Approved by the FDA
Johnson & Johnson Tecvayli (teclistamab-cqyv) Relapsed or refractory multiple myeloma in adults Approved by the FDA

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing